to investigate a p53 mutation called Y220C, which occurs in at least 30 cancer types and around 100,000 cancer patients every year. This mutation makes p53 'wobbly' - meaning it can't do its job of ...

其中，宇道生物重点介绍的p53 Y220C激动剂NTS071是一款处于临床试验启动阶段的潜在同类最佳（Best-in-Class）口服小分子。NTS071部分临床前试验的优秀 ...

It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. Receive News & Ratings for PMV ...